PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32323104-0	2020	Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.	naldemedine	159-170	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	94-99
32323104-0	2020	Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.	naldemedine	159-170	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-123
32323104-2	2020	OBJECTIVES: To assess the potential for drug-drug interactions between a single oral dose of naldemedine and the oral P-glycoprotein inhibitor cyclosporine, cytochrome P450 (CYP) 3A inhibitors itraconazole and fluconazole, and CYP3A inducer rifampin.	naldemedine	93-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	157-181
32323104-2	2020	OBJECTIVES: To assess the potential for drug-drug interactions between a single oral dose of naldemedine and the oral P-glycoprotein inhibitor cyclosporine, cytochrome P450 (CYP) 3A inhibitors itraconazole and fluconazole, and CYP3A inducer rifampin.	naldemedine	93-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	227-232
32323104-14	2020	CONCLUSIONS: Coadministration of naldemedine with a P-glycoprotein inhibitor or a strong/moderate CYP3A inhibitor increases naldemedine exposure; coadministration with a strong CYP3A inducer decreases its exposure.	naldemedine	33-44	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	177-182
32323104-14	2020	CONCLUSIONS: Coadministration of naldemedine with a P-glycoprotein inhibitor or a strong/moderate CYP3A inhibitor increases naldemedine exposure; coadministration with a strong CYP3A inducer decreases its exposure.	naldemedine	124-135	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-103
32323104-14	2020	CONCLUSIONS: Coadministration of naldemedine with a P-glycoprotein inhibitor or a strong/moderate CYP3A inhibitor increases naldemedine exposure; coadministration with a strong CYP3A inducer decreases its exposure.	naldemedine	124-135	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	177-182
30770183-3	2019	In this study, we investigated the contribution of P-glycoprotein (P-gp) on the brain distribution of naldemedine.	naldemedine	102-113	phosphoglycolate phosphatase	Mus musculus	51-65
30770183-3	2019	In this study, we investigated the contribution of P-glycoprotein (P-gp) on the brain distribution of naldemedine.	naldemedine	102-113	phosphoglycolate phosphatase	Mus musculus	67-71
30770183-6	2019	In the assessment using Caco-2 cells, it was determined that naldemedine is a substrate for P-gp.	naldemedine	61-72	phosphoglycolate phosphatase	Homo sapiens	92-96
30770183-7	2019	The contribution of P-gp to the brain distribution of naldemedine was assessed using multidrug resistance 1a/b (mdr1a/b) knockout mice.	naldemedine	54-65	phosphoglycolate phosphatase	Mus musculus	20-24
30770183-8	2019	While the brain-to-plasma concentration ratio (brain Kp) of naldemedine in the mdr1a/b knockout mice was 4-fold of that in the wild-type mice, the brain Kp in the mdr1a/b knockout mice was quite low (brain Kp < 0.1).	naldemedine	60-71	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	79-84